Therapies in Inflammatory Bowel Disease Patients with Extraintestinal Manifestations.

Juillerat, Pascal; Manz, Michael; Sauter, Bernhard; Zeitz, Jonas; Vavricka, Stephan R. (2020). Therapies in Inflammatory Bowel Disease Patients with Extraintestinal Manifestations. Digestion, 101(S1), pp. 83-97. Karger 10.1159/000502816

Text 502816.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (412kB) | Request a copy

Extraintestinal manifestations (EIM) have become an important source of morbidity and disability as well as an identified risk factor for an unfavorably course of disease in inflammatory bowel diseases (IBD). Therefore, efforts have been put into a more global and interdisciplinary management of IBD patients in collaboration with rheumatologists, dermatologists, and ophthalmologists. A real therapeutic success has also been obtained with a more "systemic" IBD treatment associated with the development of monoclonal antibodies against TNF alpha and biological agents derived from the treatment of rheumatological disease (also called biological Disease-Modifying Antirheumatic Drugs). The prevalence of these EIM remains too low to undergo randomized controlled trials with this specific focus and therefore the evidence relies on case series and experts' opinions, which lowers the level of evidence. After a careful review of the most recent literature, this paper aims to update the reader on the latest therapeutic management of IBD patients with EIM.

Interest & Impact

Downloads

1 since deposited on 22 Dec 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item